Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to a novel aminothiazole derivative having improving effects on the dysmotility in the gastrointestinal tract, a medicament containing the derivative and an intermediate for preparing said compound.
• dopamine antagonists such as domperidone and metoclopramide, opioate agonists such as trimebutine maleate, 5-HT 3 antagonists/5-HT 4 agonists such as cisapride, acetylcholine agonists such as acetylcholine chloride and the like have conventionally been provided for clinical use.
• 5-HT 3 antagonists/5-HT 4 agonists such as cisapride
• acetylcholine agonists such as acetylcholine chloride and the like
• prokinetics have been studied with a view to treating gastrointestinal dysmotility (Japanese Patent Applications Laid-Open Nos. HEI 1-313424, HEI 3-163074 and HEI 4-279581). These agents, however, do not always bring about sufficient effects for the improvement of dysmotility.
• the present invention therefore provides an aminothiazole derivative represented by the following formula (I): ##STR2## wherein R 1 , R 2 and R 3 are the same or different and each independently represents a hydrogen atom, a hydroxy group, a lower alkyl group, a lower alkoxy group, a lower alkylcarbonyloxy group, a halogen atom, a nitro group, an amino group, a mono- or di-(lower alkyl)amino group, a mono- or di-(lower alkyl)carbonylamino group, a formylamino group, a mono- or di-(lower alkyl)aminoalkylamino group, or R 1 and R 2 may be coupled together to form a methylenedioxy group; R 4 represents a hydrogen atom or a lower alkyl group; R 5 represents a hydrogen atom, a halogen atom or a lower alkyl group; A represents a group represented by the following formula: ##STR3
• the present invention also provides a medicament comprising as an effective ingredient the above-described aminothiazole derivative (I) or salt thereof.
• the present invention further provides a pharmaceutical composition
• a pharmaceutical composition comprising the above-described aminothiazole derivative (I) or salt thereof and a pharmaceutically-acceptable carrier.
• the present invention still further provides the use of the above-described aminothiazole derivative (I) or salt thereof as a medicament.
• the present invention still further provides a prevention and treatment method for the diseases caused by digestive dyskinesia, which comprises administering an effective amount of the above-described aminothiazole derivative (I) or salt thereof to a patient.
• the present invention still further provides a thiazole derivative represented by the following formula (II): ##STR5## wherein R 1 , R 2 , R 3 , R 4 and R 5 have the same meanings as defined above, and D represents a hydroxy or a lower alkoxy group or salt thereof which is useful as an intermediate for the preparation of the invention compound (I).
• lower as used herein means a linear, branched or cyclic carbon chain having 1 to 6 carbon atoms.
• examples of the "lower alkyl group” include linear, branched or cyclic alkyl groups having 1 to 6 carbon atoms (which may hereinafter be abbreviated as "C 1-6 alkyl”) such as methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, pentyl, 1-methylbutyl, 2-methylbutyl, isopentyl, tert-pentyl, 1,2-dimethylpropyl, neopentyl, 1-ethylpropyl, cyclopentyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 1-ethylbutyl, 2-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-d
• lower alkoxy group examples include linear, branched or cyclic alkoxy groups having 1 to 6 carbon atoms (which may hereinafter be abbreviated as "C 1-6 alkoxy”) such as methoxy, ethoxy, propoxy, cyclopropoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, cyclobutoxy, pentyloxy, 1-methylbutoxy, 2-methylbutoxy, isopentyloxy, tertpentyloxy, 1,2-dimethylpropoxy, neopentyloxy, 1-ethylpropoxy, cyclopentyloxy, hexyloxy, 1-methylpentyloxy, 2-methylpentyloxy, 3-methylpentyloxy, isohexyloxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethyl
• halogen atom as used herein means a fluorine, chlorine, bromine or iodine atom.
• lower alkylcarbonyl group means a linear, branched or cyclic C 2-7 alkylcarbonyl group
• lower alkylcarbonyloxy group means a linear, branched or cyclic C 2-7 alkylcarbonyloxy group.
• lower alkyl group can also be given as the examples of the lower alkyl portion of the lower alkylcarbonyl or lower alkylcarbonyloxy group.
• alkylcarbonyl group examples include acetyl, propionyl, butyryl and valeryl groups
• preferred examples of the alkylcarbonyloxy group include acetyloxy, propionyloxy, butyryloxy and valeryloxy groups.
• hydroxy(lower alkyl) group means a linear, branched or cyclic C 1-6 hydroxyalkyl group. Examples include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxy2-methylethyl, 1-hydroxycyclopropyl, 2-hydroxycyclopropyl, 1-hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-2-methylpropyl, 1-hydroxy-2,2-dimethylethyl, 1-hydroxy-1,2-dimethylethyl, 1-hydroxypentyl, 2-hydroxypentyl, 3-hydroxypentyl, 4-hydroxypentyl, 5-hydroxypentyl, 2-hydroxy-2-methylbutyl, 3-hydroxy-2-methylbutyl, 4-hydroxy-2-methylbutyl, 2-hydroxy-3-methylbutyl, 3-hydroxy-3-methylbutyl, 4-hydroxy-3-methylbutyl, 2-hydroxy4-methylbutyl,
• di- or di-(lower alkyl)amino group means an amino group substituted by one or two linear, branched or cyclic C 1-6 alkyl groups. Examples include methylamino, ethylamino, propylamino, isopropylamino, cyclopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, cyclobutylamino, pentylamino, 1-methylbutylamino, 2-methylbutylamino, isopentylamino, tert-pentylamino, 1,2-dimethylpropylamino, neopentylamino, 1-ethylpropylamino, cyclopentylamino, hexylamino, 1-methylpentylamino, 2-methylpentylamino, 3-methylpentylamino, isohexylamino,
• the "mono- or di-(lower alkyl)carbonylamino group” means an amino group substituted by one or two linear, branched or cyclic C 2-7 alkylcarbonyl groups. Examples include acetylamino, propionylamino, butyrylamino, isobutyrylamino, cyclopropylcarbonylamino, valerylamino, isovalerylamino, sec-butylcarbonylamino, pivaroylamino, cyclobutylcarbonylamino, pentylcarbonylamino, 1-methylbutylcarbonylamino, 2-methylbutylcarbonylamino, isopentylcarbonylamino, tert-pentylcarbonylamino, 1,2-dimethylpropylcarbonylamino, neopentylcarbonylamino, 1-ethylpropylcarbonylamino, cyclopentylcarbonylamino, he
• lower alkoxyalkyl group examples include C 1-6 alkoxy (C 1-6 alkyl) groups such as methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl, isobutoxymethyl, sec-butoxymethyl, tert-butoxymethyl, cyclopropoxymethyl, pentyloxymethyl, isopentyloxymethyl, hexyloxymethyl, isohexyloxymethyl, cyclopentyloxymethyl, cyclohexyloxymethyl, methoxyethyl, ethoxyethyl, propoxyethyl, isopropoxyethyl, butoxyethyl, isobutoxyethyl, sec-butoxyethyl, tert-butoxyethyl, cyclopropoxyethyl, pentyloxyethyl, isopentyloxyethyl, hexyloxyethyl, isohexyloxyethyl, is
• lower alkoxycarbonylalkyl group examples include C 1-6 alkoxycarbonyl(C 1-6 alkyl) groups such as methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, isopropoxycarbonylmethyl, butoxycarbonylmethyl, isobutoxycarbonylmethyl, sec-butoxycarbonylmethyl, tert-butoxycarbonylmethyl, cyclopropoxycarbonylmethyl, pentyloxycarbonylmethyl, isopentyloxycarbonylethyl, hexyloxycarbonylmethyl, isohexyloxycarbonylmethyl, cyclopentyloxycarbonylmethyl, cyclohexyloxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, propoxycarbonylethyl, isopropoxycarbonylethyl, butoxycarbonylethyl, isobutoxycarbonylethyl, sec-butoxycarbonyl
• carboxy(lower alkyl) group examples include carboxy(C 1-6 alkyl) groups. Among them, preferred are carboxy(C 1-4 alkyl) groups such as carboxymethyl, carboxyethyl, carboxypropyl and carboxybutyl groups.
• Examples of the "mono- or di-(lower alkyl)aminoalkyl group” include mono- or di-(C 1-6 alkyl)amino(C 1-6 alkyl) groups such as methylaminomethyl, methylaminoethyl, methylaminopropyl, methylaminobutyl, ethylaminomethyl, ethylaminoethyl, ethylaminopropyl, ethylaminobutyl, propylaminomethyl, propylaminoethyl, propylaminopropyl, propylaminobutyl, isopropylaminomethyl, isopropylaminoethyl, isopropylaminopropyl, isopropylaminobutyl, butylaminomethyl, butylaminoethyl, isobutylaminomethyl, isobutylaminoethyl, sec-butylamino
• Examples of the "mono- or di-(lower alkyl)aminoalkylamino group” include mono- or di-(C 1-6 alkyl)amino(C 1-6 alkyl)amino groups such as methylaminomethylamino, methylaminoethylamino, methylaminopropylamino, methylaminobutylamino, ethylaminomethylamino, ethylaminoethylamino, ethylaminopropylamino, ethylaminobutylamino, propylaminomethylamino, propylaminoethylamino, propylaminopropylamino, propylaminobutylamino, isopropylaminomethylamino, isopropylaminoethylamino, isopropylaminopropylamino, isopropylaminobutylamino, butylamin
• phenylalkyl group examples include phenyl(C 1-6 alkyl) groups such as benzyl, phenetyl, 1-phenylethyl, 1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, 1-methyl-1-phenylethyl, 1-ethyl-2-phenylethyl, 1-phenylbutyl, 2-phenylbutyl, 3-phenylbutyl, 4-phenylbutyl, 1-benzylpropyl, 1-methyl-1-phenylpropyl, 1-methyl-2-phenylpropyl, 1-methyl3-phenylpropyl, 2-methyl-1-phenylpropyl, 2-methyl-2-phenylpropyl, 2-methyl-3-phenylpropyl and 1,1-dimethyl-2-phenylethyl groups.
• phenyl(C 1-6 alkyl) groups such as benzyl, phenetyl, 1-phenylethyl, 1-
• lower alkylthio group examples include C 1-6 alkylthio groups such as methylthio, ethylthio, propylthio, isopropylthio, cyclopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, cyclobutylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, isopentylthio, tert-pentylthio, 1,2-dimethylpropylthio, neopentylthio, 1-ethylpropylthio, cyclopentylthio, hexylthio, 1-methylpentylthio, 2-methylpentylthio, 3-methylpentylthio, isohexylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1-d
• saturated nitrogen-containing heterocyclic group means a saturated 5-7 membered heterocyclic group containing at least one nitrogen atom in the ring thereof.
• Preferred examples include saturated 5-6 membered heterocyclic groups each containing one or two nitrogen atoms and 0 or 1 oxygen or sulfur atom, such as pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolydinyl, isooxazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino groups.
• the "unsaturated nitrogen-containing heterocyclic group” means an unsaturated 5-7 membered heterocyclic group containing at least one nitrogen atom in the ring thereof.
• Preferred are unsaturated 5-6 membered heterocyclic groups each containing 1 to 4 nitrogen atoms and 0 or 1 oxygen or sulfur atom.
• Specific examples include pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, isooxazolyl, isothiazolyl, pyridyl, dihydropyridyl and tetrahydropyridyl groups.
• branched alkylamino group examples include branched C 2-6 alkylamino groups, more specifically, isopropylamino, sec-butylamino and isobutylamino groups.
• piperidinylalkylamino group examples include piperidinyl (C 1-6 alkyl)amino groups, more specifically, piperidinylmethylamino and piperidinylethylamino groups.
• one of R 1 , R 2 and R 3 represents a lower alkoxy, nitro or formylamino group and the other two are selected from a hydrogen atom, a hydroxy group, a lower alkyl group, a lower alkoxy group, a lower alkylcarbonyloxy group, a halogen atom, a nitro group, an amino group, a mono- or di-(lower alkyl)amino group, mono- or di-(lower alkyl)carbonylamino group, formylamino group and mono- or di-(lower alkyl)aminoalkylamino group.
• the nitrogen-containing heterocyclic group represented independently by R 6 and R 7 piperidinyl, piperazinyl and pyridyl groups are particularly preferred.
• nitrogen-containing heterocyclic group which is formed by R 6 and R 7 together with the adjacent nitrogen atom
• saturated nitrogen-containing heterocyclic groups are preferred, with pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, isooxazolidinyl and morpholino groups being particularly preferred.
• nitrogen-containing saturated heterocyclic group which is formed by R 8 and R 9 together with the adjacent carbon atom
• pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl groups are particularly preferred.
• R 1 , R 2 and R 3 represents a lower alkoxy, nitro or formylamino group and the other two are selected from a hydrogen atom, a hydroxy group, a lower alkyl group, a lower alkoxy group, a lower alkylcarbonyloxy group, a halogen atom, a nitro group, an amino group, a mono- or di-(lower alkyl)amino group, a mono or di-(lower alkyl)carbonylamino group, a formylamino group and a mono- or di-(lower alkyl)aminoalkylamino group;
• R 4 represents a hydrogen atom or a lower alkyl group;
• R 5 represents a hydrogen atom, a halogen atom or a lower alkyl group;
• A represents --N(R 6 )R 7 (in which R 6 and R 7 have the same meanings as defined above);
• B represents an imino group which may be
• R 1 , R 2 and R 3 represents a lower alkoxy, nitro or formylamino group and the other two are selected from a hydrogen atom, a hydroxy group, a lower alkoxy group and a halogen atom;
• R 4 and R 5 each represents a hydrogen atom;
• B represents an imino group which may be substituted by a lower alkyl group;
• m stands for 2 to 4;
• A represents --N(R 6 )R 7 (in which R 6 and R 7 have the same meanings as defined above).
• the invention compound (I) or intermediate (II) for the preparation of the invention compound can be converted into its salt in a manner known per se in the art.
• the salt of the invention compound (I) or intermediate (II) include acid addition salts with an inorganic acid, such as hydrochloride, sulfate, nitrate, phosphate, hydrobromide and hydroiodide; and acid addition salts with an organic acid such as acetate, oxalate, malonate, succinate, maleate, fumarate, lactate, malate, citrate, tartrate, methanesulfonate and ethanesulfonate.
• the present invention also embraces various solvates, such as hydrates, of the invention compound (I) or the intermediate (II).
• the invention compound (I) sometimes exhibits proton tautomerism, particularly imine-enamine tautomerism.
• Examples of such tautomerism include: ##STR6##
• the invention compound (I) or the intermediate (II) can be prepared by various synthesis processes, with its basic skeleton or characteristics of its group taken into consideration. Typical synthesis processes (A and B) for it will be described below. Here, it is possible to prepare the invention compound by any one of the preparation process A, preparation process B and processes in accordance therewith.
• Preparation Process A ##STR7## wherein X represents an eliminating group such as p-nitrophenoxy group, a halogen atom or a hydroxy group, and R 1 , R 2 , R 3 , R 4 , R 5 , A, B, D and m have the same meanings as defined above.
• a thiazole derivative (II) can be prepared by reacting the compound represented by the formula (III) with the compound represented by the formula (IV).
• the reaction is carried out in the presence or absence of a base, for example, an alkali metal carbonate such as potassium carbonate, potassium bicarbonate, sodium carbonate or sodium bicarbonate, an alkali metal hydroxide such as potassium hydroxide, sodium hydroxide or lithium hydroxide, an alkylamine such as triethylamine or diisopropylethylamine, or a pyridine base compound such as pyridine, lutidine or 4-dimethylaminopyridine in a solventless manner or in a solvent which does not exert an influence on the reaction, for example, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a halogen base solvent such as methylene chloride, chloroform or 1,2-dichloroethane, an ether base solvent such as
• X of Compound (III) represents a hydroxy group
• the main reaction can be carried out after it is converted into a highly reactive substituent such as p-nitrophenoxy group or halogen atom in a manner known per se in the art.
• the main reaction is effected after protection of the amino group of Compound (III), followed by deprotection after the main reaction or after the reaction in the subsequent step A2; or the main reaction is effected by using a nitro-containing Compound (III), followed by reduction after the main reaction or after the reaction in the step A2 to convert the nitro group into an amino group.
• the invention compound (I) can be obtained by reacting the thiazole derivative (II) obtained in the step Al with Compound (V) and then subjecting the reaction mixture to N-substitution reaction as needed.
• the reaction is effected as in Step A1.
• D of the thiazole derivative (II) represents a hydroxy group
• D of the thiazole derivative (II) represents a hydroxy group
• the invention compound (I) can be introduced into another invention compound (I) by subjecting it to N-substitution reaction or O-substitution reaction.
• the N-substitution reaction can be effected by the method known to date such as monoalkylation, dialkylation or amidation.
• the N-substitution can be carried out as needed by the reaction in which a reducing agent such as formic acid or boron hydride compound and an aldehyde such as formaldehyde, acetaldehyde or glyoxal or an acid anhydride such as acetic anhydride are used in combination, the reaction in which a carboxylic acid or reactive derivative thereof is used, the reaction in which an alkyl halide is used, the reaction in which a compound containing therein an eliminating group such as lower alkoxy, lower alkylthio, lower alkylsulfonyl or lower alkylsulfinyl, or a halogen atom is used, the reduction reaction in which an aldehyde or ketone is acted to form an imine derivative, followed by the addition of a boron hydride compound or the hydrogenation reaction in which a palladium carbon or the like is used as a catalyst, or a combination thereof.
• a reducing agent such as formic acid
• a phthalimide-substituted alkyl halide when employed in the N-substitution reaction using an alkyl halide, it is possible to convert the phthalimide group into an amino group by a base such as methylamine (Gabriel synthesis) and then subject the resulting amino group to the N-substitution reaction.
• a base such as methylamine (Gabriel synthesis)
• the O-substitution reaction can be effected by the method known to date such as alkylation or acylation. It is possible to effect the O-substitution reaction as needed in accordance with the reaction in which a carboxylic acid or reactive derivative thereof is used or the reaction in which an alkyl halide is used, or a combination thereof.
• Compound (V) a commercially-available compound can be employed or alternatively, it can be prepared by using the above-described reactions for N-substitution in combination as needed.
• Compound (VI) can be prepared by reacting Compound (IV) with Compound (V). The reaction is effected in a similar manner to Step A2.
• Step B1 Compound (VI) obtained in Step B1 can be introduced into the invention compound (I) by being reacted with Compound (III). The reaction is effected in a similar manner to Step A1.
• the main reaction is effected after the protection of the amino group of Compound (III), followed by deprotection; or the main reaction is effected using a nitro-containing Compound (III), followed by reduction after the main reaction to convert the nitro group into an amino group.
• the thiazole derivative (II) or invention compound (I) containing as any one of R 1 , R 2 and R 3 a hydroxy group is prepared, it is possible to use an alkoxycontaining Compound (III) instead of using a hydroxycontaining Compound (III).
• the alkoxy-containing Compound (III) is used, the derivative or the invention compound is prepared, subsequent to the main reaction or the reaction in Step A2, by the dealkylation reaction using pyridine hydrochloride, boron tribromide, a solution of hydrogenbromide solution in acetic acid, or catalytic reduction to convert the alkoxy group into a hydroxy group.
• Invention Compound (I) prepared by any one of the above-described Preparation Processes A and B and processes in accordance therewith can be prepared in the form of a salt in a manner known per se in the art.
• Invention Compound (I) so obtained has, as will be described later, excellent improving effects on gastrointestinal dysmotility and at the same time has high safety so that it is useful for the prevention and treatment of dysmotility in the gastrointestinal tract.
• Examples of the symptoms and diseases caused by digestive dysmotility include epigastric dyscomfort, nausea, vomiting, heart burn, anorexia, epigastric pain, abdominal flatulence, chronic gastritis, reflux esophagitis and postgastrectomy syndrome.
• the invention compound (I) can be formed as a composition for oral or parenteral administration, mixed with a pharmaceutically acceptable carrier.
• the invention compound (I) can be formulated into tablets, powders, granules or capsules by adding suitable additives, for example, an excipient such as lactose, mannitol, corn starch or crystalline cellulose, a binder such as cellulose derivative, gum arabic or gelatin, a disintegrator such as carboxymethyl cellulose calcium and a lubricant such as talc or magnesium stearate as needed.
• suitable additives for example, an excipient such as lactose, mannitol, corn starch or crystalline cellulose, a binder such as cellulose derivative, gum arabic or gelatin, a disintegrator such as carboxymethyl cellulose calcium and a lubricant such as talc or magnesium stearate as needed.
• a covering base such as hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate or methacrylate copolymer.
• the invention compound can be formulated into a liquid agent for injection by using water, ethanol, glycerin and ordinarily-used surfactant, or into a suppository by using a suppository base in combination.
• the dosage of the invention compound (I) varies depending on the age, weight, symptom, treatment effects, administration method and administration term.
• the compound (I) is generally administered at a dose of 0.1 to 2,000 mg/day, preferably 1 to 300 mg/day in one to three portions a day. (Gastroprokinetic activity)
• Force transducers (F-121S; Star Medical) were chronically implanted onto the gastric antrum and duodenum of a male dog (weight: 9 to 10 kg) [Itoh, Z. et al., Am. J. Dig. Dis., 22, 117-124(1977)]. The test was carried out two hours after feeding (30 g/kg, Gaines meal; Ajinomoto General Foods). Contraction signals obtained from each transducer were amplified (RTA-1200; Nihon Kohden) and recorded on a recorder and a computer.
• the area under the contraction wave and base line in the antrum was integrated by an analysis program (DSSFFT, V. 21; Nihon Kohden). Motor activity in the antrum was expressed as the motor index.
• the test compound was dissolved in physiological saline and given intravenously.
• Test compound suspended with 5% gum arabic was given orally at a dose of 500 mg/kg. Within one week observation, no case of death was observed in each group.
• IR(KBr)cm -1 3400, 3200, 2966, 2689, 1690, 1670, 1580, 1560, 1520; 1 H-NMR(DMSO-d 6 ) ⁇ : 2.80(3H,s), 2.82(3H,s), 3.26(2H,q), 3.68(2H,q), 3.86(3H,s), 6.91(1H,brs), 7.71-7.24(1H,m), 7.47(1H,t), 7.65-7.70(2H,m), 8.01(1H,s), 8.39(1H,t), 10.68(1H,brs), 12.84(1H,brs).
• IR(KBr)cm -1 3400, 3150, 3050, 2950, 2700, 1670, 1655, 1603; 1 H-NMR(DMSO-d 6 ) ⁇ : 2.80(3H,s), 2.82(3H,s), 3.25(2H,q), 3.68(2H,q), 3.85(3H,s), 4.68(1H,s), 7.05-7.15(2H,m), 7.96(1H,s), 8.01-8.15(2H,m), 8.36(1H,t), 10.54(1H,s), 12.64 (1H, s)
• IR(KBr)cm -1 3450, 1680, 1636, 1559, 1279;
• IR(KBr)cm -1 3400, 3320, 1640, 1625; 1 H-NMR(CDCl 3 ) ⁇ : 1.23(6H,t), 3.14(3H,s), 3.15(2H,q), 3.29(2H,t), 3.76(3H,s), 3.77(4H,q), 3.92(3H,s), 4.03(3H,s), 6.02(2H,s), 6.86(3H,s), 7.49(1H,s), 7.65(1H,s), 9.50(2H,brs), 11.26(1H,s).
• IR(KBr)cm -1 3400, 1663, 1611, 1550; 1 H-NMR(DMSO-d 6 ) ⁇ : 0.91(6H,t), 1.65-1.80(4H,m), 3.00-3.10(4H,m), 3.20-3.25(2H,m), 3.60-3.70(2H,m), 3.79(3H,s), 3.93(3H,s), 4.08(3H,s), 6.89(1H,s), 7.50(1H,s), 7.91(1H,s), 8.69(1H,t), 10.55(2H,brs), 11.32(1H,s).
• IR(KBr)cm -1 3450, 1675, 1600, 1609; 1 H-NMR(DMSO-d 6 ) ⁇ : 1.32(6H,t), 3.07(2H,t), 3.11-3.40(4H,m), 3.70-3.80(4H,m), 3.71(3H,s), 3.75(3H,s), 3.79(3H,s), 3.93(3H,s), 4.08(3H,s), 6.79-6.93(3H,m), 7.51(1H,s), 7.91(1H,s), 8.77(1H,t), 10.52(1H,brs), 11.34(1H,s).
• IR(KBr)cm -1 3300, 2980, 2960, 2600, 2500, 1670, 1650, 1600; 1 H-NMR(DMSO-d 6 ) ⁇ : 1.11(12H,d), 1.31(3H,t), 1.38(3H,t), 2.75-2.85(2H,m), 3.18-3.35(2H,m), 3.35-3.45(2H,m), 3.80(2H,brs), 4.02(2H,q), 4.04(3H,s), 4.20(2H,q), 6.59(2H,s), 6.85(1H,s), 7.49(1H,s), 7.83(1H,s), 8.37(1H,brs), 11.29(1H,s).
• IR(KBr)cm -1 3400, 3200, 1686, 1665, 1617, 1553; 1 H-NMR(DMSO-d 6 ) ⁇ : 0.93(3H,t), 1.27(3H,d), 1.28(3H,d), 1.73-1.82(2H,m), 3.00-3.17(4H,m), 3.20-3.35(1H,m), 3.57-3.78(2H,m), 3.80(3H,s), 3.98(3H,s), 6.00-6.30(2H,br), 6.79(1H,s), 7.52(1H,s), 7.89(1H,s), 8.70(1H,t), 10.20(1H,brs), 11.22(1H,s).
• IR(KBr)cm -1 3400, 3350, 3220, 1655, 1601; 1 H-NMR(CDCl 3 , measured was a compound in the form of a free base) ⁇ : 2.30(6H,s), 2.53(2H,t), 3.53(2H,q), 4.07(3H,s), 4.59(2H,brs), 6.35(1H,s), 7.73(1H,s), 7.45(1H,brs), 8.19(1H,s), 10.79(1H,s).
• the above-described ingredients were uniformly mixed.
• the resulting mixture was pressed into 200-mg tablets by a punch of 7.5 mm in diameter on a single punch tableting machine.
• an injection was prepared in a manner known per se in the art.
• the compound according to the present invention markedly enhances gastrointestinal motility, thereby bringing about an improvement in the digestive dysmotility and at the same time, exhibits high safety so that it is useful for the prevention and treatment of various digestive dysmotility.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=15314454

Family Applications (1)

Country Status (14)

Cited By (19)

Families Citing this family (26)

Citations (2)

Family Cites Families (5)

• 1996
  • 1996-05-16 US US08/952,106 patent/US5981557A/en not_active Expired - Lifetime
  • 1996-05-16 AU AU57024/96A patent/AU699008B2/en not_active Expired
  • 1996-05-16 EP EP96915167A patent/EP0870765B1/en not_active Expired - Lifetime
  • 1996-05-16 PT PT96915167T patent/PT870765E/pt unknown
  • 1996-05-16 WO PCT/JP1996/001297 patent/WO1996036619A1/ja active IP Right Grant
  • 1996-05-16 DE DE69630806T patent/DE69630806T2/de not_active Expired - Lifetime
  • 1996-05-16 KR KR1019970707808A patent/KR100424933B1/ko not_active IP Right Cessation
  • 1996-05-16 CA CA002219747A patent/CA2219747C/en not_active Expired - Lifetime
  • 1996-05-16 DK DK96915167T patent/DK0870765T3/da active
  • 1996-05-16 ES ES96915167T patent/ES2210366T3/es not_active Expired - Lifetime
  • 1996-05-16 CN CN96194002A patent/CN1063442C/zh not_active Expired - Lifetime
  • 1996-05-16 AT AT96915167T patent/ATE254609T1/de active
  • 1996-05-16 JP JP53470396A patent/JP3181919B2/ja not_active Expired - Lifetime
  • 1996-05-17 TW TW085105855A patent/TW445260B/zh not_active IP Right Cessation

Patent Citations (2)

Also Published As

Similar Documents

Legal Events